Decoy Therapeutics Inc. (DCOY)
| Market Cap | 4.58M +159.3% |
| Revenue (ttm) | n/a |
| Net Income | -13.03M |
| EPS | -57.12 |
| Shares Out | 531.97K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 21,068 |
| Open | 8.56 |
| Previous Close | 8.36 |
| Day's Range | 8.01 - 9.00 |
| 52-Week Range | 4.32 - 415.80 |
| Beta | 0.38 |
| Analysts | Strong Buy |
| Price Target | 30.00 (+248.43%) |
| Earnings Date | May 8, 2026 |
About DCOY
Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design α-helical peptides through computational and ML tools. The company’s IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, enhance, and manufacture peptide conjugates targeting ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for DCOY stock is "Strong Buy" and the 12-month stock price target is $30.0.
News
Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors
CAMBRIDGE, Mass., June 3, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered...
Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV™ Candidate into the Clinic
Collaboration supports Phase 1 and Phase 2a human proof-of-concept studies for new antiviral category designed to address multiple viruses with a single adaptable therapeutic CAMBRIDGE, Mass., June 1,...
Decoy Therapeutics Names Brad Pentelute, MIT Professor of Chemistry, as Chair of Scientific Advisory Board
Appointment deepens scientific leadership as Decoy advances its Designable Multi-Antiviral pipeline toward clinical development NEW YORK and CAMBRIDGE, Mass., May 26, 2026 /PRNewswire/ -- Decoy Therap...
Decoy Therapeutics Quarterly report: Q1 2026
Decoy Therapeutics has published its Q1 2026 quarterly earnings report on May 8, 2026.
Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston
CBO Peter Marschel to Lead HubXchange Roundtable on Computational Peptide Design CSO Dr. Barbara Hibner and CTO Dr. Michael Lipp to Co-Present at Peptide-Based Therapeutics Summit; Advisor Dr. Bradley...
Decoy Therapeutics Transcript: Status update
AI-designed multi-antivirals are advancing toward clinical trials, targeting large unmet needs in respiratory infections with rapid, cost-effective development and broad-spectrum efficacy. Strategic partnerships and non-dilutive funding support growth, with significant milestones expected in the next 12–24 months.
Decoy Therapeutics Press release: Status update
Decoy Therapeutics issued a press release on April 9, 2026, disclosing material business information to investors.
Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline
Highly differentiated AI-powered D-MAV discovery platform targeting drugdiscovery in the multi-billion-dollar antiviral markets Company to participate in Virtual Investor Closing Bell event to discuss...
Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026
Live video webcast with Rick Pierce, Chief Executive Officer of Decoy Therapeutics, on Thursday, April 9 th at 4:00 PM ET Register for the event here CAMBRIDGE, Mass. and HOUSTON, April 6, 2026 /PRNew...
Decoy Therapeutics regains Nasdaq compliance
Decoy Therapeutics (DCOY) announces that on March 31, the company received notification from the Nasdaq Stock Market that it has regained compliance with Listing Rule 5550(a)(2), the Minimum Bid Price...
Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
CAMBRIDGE, Mass. and HOUSTON, April 2, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), announces that on March 31, 2026 the Company received notification from the...
Decoy Therapeutics Annual report: Q4 2025
Decoy Therapeutics has published its Q4 2025 annual report on March 31, 2026.
Decoy Therapeutics enters collaboration with Quantori
Decoy Therapeutics (DCOY) announced a collaboration with Quantori, a provider of digital transformation services and technology for the life sciences and healthcare industries, supported by funding fr...
Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform
Partnership supported by funding from Google Cloud will increase Decoy's computational peptide design bandwidth by 25-100x CAMBRIDGE, Mass. and HOUSTON, March 11, 2026 /PRNewswire/ -- Decoy Therapeuti...
Decoy Therapeutics Inc trading halted, news pending
19:50 EST Decoy Therapeutics (DCOY) Inc trading halted, news pending
Decoy Therapeutics announces 1-for-12 reverse stock split
Decoy Therapeutics (DCOY) announced that it will effect a 1-for-12 reverse stock split at 5:00 p.m. Eastern Time, on March 6. Beginning with the opening of trading on March 9,…
Decoy Therapeutics Announces 1-for-12 Reverse Stock Split
CAMBRIDGE, Mass., March 5, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (NASDAQ: DCOY), a preclinical-stage biopharmaceutical company that is engineering the next generation of peptide conjugate thera...
Decoy Therapeutics Joins Webull Corporate Connect Service Platform
- Connect with the Company on Webull here CAMBRIDGE, Mass. and HOUSTON, Feb. 11, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), a preclinical biopharmaceutical ...
Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
– Live video webcast on Tuesday, February 10th at 1:20 PM EST CAMBRIDGE, Mass. and HOUSTON, Feb. 5, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), a preclinical ...
Decoy Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recently Announced Global Access Commitment Agreement
Access the "What This Means" segment here CAMBRIDGE, Mass. and HOUSTON, Feb. 4, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), a preclinical biopharmaceutical th...
Decoy Therapeutics initiated with a Buy at Ladenburg
Ladenburg initiated coverage of Decoy Therapeutics (DCOY) with a Buy rating and $2.50 price target
Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform
Decoy Therapeutics will use the platform, with funding support from the Gates Foundation, to provide widespread access to peptide-conjugate antivirals from Decoy's IMP 3 ACT™ platform for low- and mid...
Decoy Therapeutics Proxy statement: Proxy Filing
Decoy Therapeutics filed a proxy statement on January 9, 2026, providing details for shareholder voting and corporate governance matters.
Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics
Trading under DCOY to commence on January 8, 2026 Company's proprietary peptide-conjugate platform leverages AI-enabled computational infrastructure to accelerate candidate selection Capital-efficient...
Decoy Therapeutics Proxy statement: Proxy Filing
Decoy Therapeutics filed a proxy statement on December 29, 2025, providing details for shareholder voting and corporate governance matters.